IFETROBAN
Ifetroban is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target thromboxane A2 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
No data
Clinical
No data
Drug
General
| Drug common name | IFETROBAN |
| INN | ifetroban |
| Description | Ifetroban is a potent and selective thromboxane receptor antagonist. It has been studied in animal models for the treatment of cancer metastasis, myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy, and for its effects on platelets. Clinical trials are evaluating the therapeutic safety and efficacy of oral ifetroban capsules for the treatment of cancer metastasis, cardiovascular disease, aspirin exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy.
|
| Classification | Small molecule |
| Drug class | antithrombotics (thromboxane A2 receptor antagonists) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCNC(=O)c1coc([C@@H]2[C@H]3CC[C@H](O3)[C@@H]2Cc2ccccc2CCC(=O)O)n1 |
Identifiers
| PDB | — |
| CAS-ID | 143443-90-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301673 |
| ChEBI ID | — |
| PubChem CID | 23724921 |
| DrugBank | DB12321 |
| UNII ID | E833KT807K (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use